Όλο το DSpace

Εμφάνιση απλής εγγραφής

Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive

dc.creatorKontopoulou K., Ainatzoglou A., Nakas C.T., Ifantidou A., Goudi G., Antoniadou E., Adamopoulos V., Papadopoulos N., Papazisis G.en
dc.date.accessioned2023-01-31T08:44:06Z
dc.date.available2023-01-31T08:44:06Z
dc.date.issued2021
dc.identifier10.1016/j.vaccine.2021.07.065
dc.identifier.issn0264410X
dc.identifier.urihttp://hdl.handle.net/11615/75093
dc.description.abstractThis study monitored titers of neutralizing IgG against the receptor-binding domain of the SARS-CoV-2 S1 subunit 14 days post-injection of each dose of the BNT162b2 mRNA Covid-19 vaccine in 401 Greek healthcare workers aged 20–67. After the first dose, titers varied upon age and history of infection, being lower in the 50+ age group and significantly higher among the seropositive. After the second dose, immunogenicity was significantly boosted in the age 50+ and SARS-CoV-2-naïve individuals, indicating the effectuality of its timely administration, yet questioning its value among the seropositive. © 2021 Elsevier Ltden
dc.language.isoenen
dc.sourceVaccineen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85111607466&doi=10.1016%2fj.vaccine.2021.07.065&partnerID=40&md5=71de1726c8c7af4c8d5158b1d8f8ee6a
dc.subjectcomirnatyen
dc.subjectimmunoglobulin Gen
dc.subjectbnt 162 vaccineen
dc.subjectmessenger RNAen
dc.subjectvirus antibodyen
dc.subjectadulten
dc.subjectageden
dc.subjectagingen
dc.subjectArticleen
dc.subjectcontrolled studyen
dc.subjectcoronavirus disease 2019en
dc.subjectdrug efficacyen
dc.subjectfemaleen
dc.subjectGreek (citizen)en
dc.subjecthealth care personnelen
dc.subjecthumanen
dc.subjectimmunogenicityen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectmedical historyen
dc.subjectreceptor bindingen
dc.subjectSevere acute respiratory syndrome coronavirus 2en
dc.subjectmiddle ageden
dc.subjectAntibodies, Viralen
dc.subjectCOVID-19en
dc.subjectCOVID-19 Vaccinesen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectRNA, Messengeren
dc.subjectSARS-CoV-2en
dc.subjectElsevier Ltden
dc.titleSecond dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositiveen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής